122 related articles for article (PubMed ID: 21892039)
1. Noninvasive and invasive staging of ovarian cancer: review of the literature.
Fuccio C; Castellucci P; Marzola MC; Al-Nahhas A; Fanti S; Rubello D
Clin Nucl Med; 2011 Oct; 36(10):889-93. PubMed ID: 21892039
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET/CT as a molecular biomarker in ovarian cancer.
Nowosinska E; Avril S; Murray I; Szyszko T; Avril N
Cancer Biomark; 2010-2011; 8(4-5):167-75. PubMed ID: 22045351
[TBL] [Abstract][Full Text] [Related]
3. Characterization of tubo-ovarian abscess mimicking adnexal masses: Comparison between contrast-enhanced CT,
Fan H; Wang TT; Ren G; Fu HL; Wu XR; Chu CT; Li WH
Taiwan J Obstet Gynecol; 2018 Feb; 57(1):40-46. PubMed ID: 29458901
[TBL] [Abstract][Full Text] [Related]
4. Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment.
Nasu K; Abe W; Takai N; Tomonari K; Narahara H
Arch Gynecol Obstet; 2011 May; 283(5):1121-6. PubMed ID: 20574659
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy.
De Iaco P; Musto A; Orazi L; Zamagni C; Rosati M; Allegri V; Cacciari N; Al-Nahhas A; Rubello D; Venturoli S; Fanti S
Eur J Radiol; 2011 Nov; 80(2):e98-103. PubMed ID: 20688446
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
[TBL] [Abstract][Full Text] [Related]
7. Present and future of FDG-PET/CT in ovarian cancer.
Kitajima K; Murakami K; Sakamoto S; Kaji Y; Sugimura K
Ann Nucl Med; 2011 Apr; 25(3):155-64. PubMed ID: 21113691
[TBL] [Abstract][Full Text] [Related]
8. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
9. Fludeoxyglucose F 18 PET-Computed Tomography: Management Changes Effecting Patient Outcomes in Gynecologic Malignancies.
Brunetti JC
PET Clin; 2015 Jul; 10(3):395-409. PubMed ID: 26099674
[TBL] [Abstract][Full Text] [Related]
10. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
11. [PET/CT scan with (18)F-FDG in re-staging of an atypical case of ovarian cancer].
García Gómez FJ; Cuenca Cuenca JI; Acevedo Báñez I; Borrego Dorado I; Calvo García E; Vázquez Albertino RJ
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):223-4. PubMed ID: 23067691
[No Abstract] [Full Text] [Related]
12. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.
Nanni C; Rubello D; Farsad M; De Iaco P; Sansovini M; Erba P; Rampin L; Mariani G; Fanti S
Eur J Surg Oncol; 2005 Sep; 31(7):792-7. PubMed ID: 15893908
[TBL] [Abstract][Full Text] [Related]
13. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization.
Iyer VR; Lee SI
AJR Am J Roentgenol; 2010 Feb; 194(2):311-21. PubMed ID: 20093590
[TBL] [Abstract][Full Text] [Related]
14. Plasmacytoma of the ovary: additional role of 18F-FDG PET/CT.
Santhosh S; Mittal BR; Raveendran A; Jain V; Nijhawan R; Kumar R; Bhattacharya A; Sharma SC
Clin Nucl Med; 2013 May; 38(5):e230-2. PubMed ID: 23377413
[TBL] [Abstract][Full Text] [Related]
15. Calcified metastases from ovarian carcinoma highlighted by F-18 FDG PET/CT: report of two cases.
Hu SL; Zhou ZR; Zhang YJ
Abdom Imaging; 2012 Aug; 37(4):675-9. PubMed ID: 21898082
[TBL] [Abstract][Full Text] [Related]
16. 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
Mertens LS; Mir MC; Scott AM; Lee ST; Fioole-Bruining A; Vegt E; Vogel WV; Manecksha R; Bolton D; Davis ID; Horenblas S; van Rhijn BW; Lawrentschuk N
Urology; 2014 Feb; 83(2):393-8. PubMed ID: 24468513
[TBL] [Abstract][Full Text] [Related]
17. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
[TBL] [Abstract][Full Text] [Related]
18. Management of epithelial ovarian cancer from diagnosis to restaging: an overview of the role of imaging techniques with particular regard to the contribution of 18F-FDG PET/CT.
Musto A; Grassetto G; Marzola MC; Rampin L; Chondrogiannis S; Maffione AM; Colletti PM; Perkins AC; Fagioli G; Rubello D
Nucl Med Commun; 2014 Jun; 35(6):588-97. PubMed ID: 24535383
[TBL] [Abstract][Full Text] [Related]
19. Extraovarian primary peritoneal carcinoma: staging with 18F-FDG PET/CT.
Rakheja R; Makis W; Hickeson M
Abdom Imaging; 2012 Apr; 37(2):304-8. PubMed ID: 21394599
[TBL] [Abstract][Full Text] [Related]
20. [18F-FDG PET/CT in patients, treated for ovarian cancer, with elevated CA 125 levels but no evidence of recurrence on conventional imaging].
Bochev P; Bocheva Y; Klisarova A; Ivanov S; Dancheva J; Chaushev B
Akush Ginekol (Sofiia); 2012; 51(1):18-27. PubMed ID: 22639775
[No Abstract] [Full Text] [Related]
[Next] [New Search]
